On July 21, 2026, an international research team led by Pasquale Caponnetto from the University of Catania published a review in Frontiers in Psychiatry evaluating the impact of e-cigarettes on smokers with schizophrenia spectrum disorders. Analyzing clinical data from 2020 to early 2026, the researchers found that vaping serves as an effective harm-reduction strategy for a patient demographic where traditional smoking cessation therapies fail over 90% of the time.
The High Toll of Smoking in Schizophrenia
Smoking rates among individuals with schizophrenia are two to four times higher than in the general population. Consequently, tobacco use is the leading cause of premature death in this group, reducing life expectancy by 15 to 20 years due to cardiovascular, oncological, and respiratory diseases.
Standard cessation methods—such as nicotine replacement therapy, bupropion, varenicline, and behavioral counseling—show a success rate of under 10% for these patients. Because complete nicotine abstinence is difficult to achieve, researchers are evaluating electronic cigarettes as a tool to deliver nicotine without the toxic combustion products of tobacco.
Analysis of Key Clinical Trials
The review analyzed data from three prospective studies involving 323 participants. These trials monitored smoking reduction, biomarkers of harm, and psychiatric stability.
| Study | Country & Device Used | Participant Profile | Key Outcomes |
|---|---|---|---|
| Caponnetto et al. (2021) | Italy; JUUL (5% nicotine pod) | 40 patients with schizophrenia or schizoaffective disorder | 87.5% halved their cigarette consumption; 40% quit smoking entirely by week 12. No psychiatric decline. |
| Pratt et al. (2022, 2025) | US; NJOY disposable vape | 68 patients with severe mental illness (SMI) | 50% reduction in daily cigarettes. Urinary NNAL (carcinogen marker) dropped at 4 weeks, but dual-use rose by week 8. |
| Kale & Beard (2025) | UK; Aspire PocketX (0.6%–1.8% nicotine) | 43 patients with various psychiatric conditions | 61.9% reduced smoking by half; 9.5% quit smoking entirely. No psychiatric deterioration. |
Key Findings: Safety, Carcinogens, and the Clozapine Interaction
The review highlighted several critical outcomes regarding the use of e-cigarettes in psychiatric care:
- Feasibility: Patients across all trials willingly adopted vaping devices and showed high adherence rates, indicating that vaping is an acceptable alternative in clinical settings.
- Reduction in Carcinogens: Researchers measured exhaled carbon monoxide (CO) and urinary NNAL (a metabolite of a major tobacco carcinogen). While both markers dropped, the reduction was only sustained when patients completely substituted cigarettes with vapes. Dual-use—vaping while continuing to smoke—negated these benefits.
- Psychiatric Stability: Crucially, none of the studies recorded an increase in psychotic symptoms, anxiety, or depression. This addresses a primary concern among psychiatrists that changing nicotine delivery methods might destabilize patients.
The Critical Clozapine Interaction
A vital clinical finding involves clozapine, an antipsychotic prescribed for treatment-resistant schizophrenia. Chemicals in tobacco smoke induce the CYP1A2 liver enzyme, which metabolizes clozapine, requiring smokers to take higher doses of the medication.
When a patient switches to vaping, the absence of tobacco smoke stops this enzyme induction. This can cause clozapine levels in the blood to rise to toxic levels, potentially leading to severe sedation, seizures, or worsened psychosis. The authors emphasize that any transition to vaping for patients on clozapine must include blood-level monitoring and dose adjustments.
Study Limitations and Recommendations
The authors noted several limitations in the current research, including a small overall sample size (323 participants), diagnostic heterogeneity (only the Italian study focused exclusively on schizophrenia), and short observation periods (mostly up to 12 weeks). Additionally, some authors reported financial ties to pharmaceutical or vaping industries.
Clinically, the review suggests that vaping can be a practical harm-reduction option when combined with behavioral support to prevent dual-use. Regulatory approaches vary globally: the UK supports vaping as a cessation tool, Australia permits it as a second-line option for psychiatric patients, and the US regulates vapes as consumer products rather than approved medical devices.
While early data is promising, larger, longer-term trials are needed to define the role of e-cigarettes in psychiatric clinical practice.
